Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VKTX 
Viking Therapeutics Inc (VKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: VKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $92.29
1 Year Target Price $92.29
| 10 | Strong Buy |
| 7 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.51% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.79B USD | Price to earnings Ratio - | 1Y Target Price 92.29 |
Price to earnings Ratio - | 1Y Target Price 92.29 | ||
Volume (30-day avg) 19 | Beta 0.72 | 52 Weeks Range 18.92 - 81.73 | Updated Date 09/13/2025 |
52 Weeks Range 18.92 - 81.73 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.99% | Return on Equity (TTM) -19.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1982913482 | Price to Sales(TTM) - |
Enterprise Value 1982913482 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -71.64 | Shares Outstanding 112445000 | Shares Floating 219960335 |
Shares Outstanding 112445000 | Shares Floating 219960335 | ||
Percent Insiders 2.15 | Percent Institutions 68.38 |
Upturn AI SWOT
Viking Therapeutics Inc
Company Overview
History and Background
Viking Therapeutics Inc. was founded in 2014. It is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Core Business Areas
- VK2809 Development: Development of VK2809, a selective thyroid hormone receptor beta agonist, for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
- VK0612 Development: Development of VK0612, an oral small molecule, for the treatment of type 2 diabetes.
- VK2735 Development: Development of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, for the potential treatment of obesity and metabolic disorders.
Leadership and Structure
Viking Therapeutics is led by Brian Lian, Ph.D., President and CEO. The organizational structure includes teams focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- VK2809: VK2809 is Viking's lead drug candidate for NASH. While no market share data is available yet (as it is still in clinical trials), potential competitors include Madrigal Pharmaceuticals (MDGL), Akero Therapeutics (AKRO), and 89bio (ETNB).
- VK2735: VK2735 is a dual GLP-1/GIP agonist being developed for obesity. The potential market is very large. Competitors include Eli Lilly (LLY) with Tirzepatide (Mounjaro) and Novo Nordisk (NVO) with Semaglutide (Wegovy).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and strict regulatory requirements. The market for NASH and obesity treatments is large and growing rapidly.
Positioning
Viking Therapeutics is positioned as an innovative company focused on developing differentiated therapies for metabolic disorders. Its competitive advantage lies in its novel drug candidates and experienced management team.
Total Addressable Market (TAM)
The total addressable market for NASH and obesity treatments is estimated to be billions of dollars. Viking is positioned to capture a significant share of this market if its drug candidates are approved.
Upturn SWOT Analysis
Strengths
- Promising drug candidates in clinical development
- Experienced management team
- Strong intellectual property portfolio
- Focus on large and growing markets
Weaknesses
- High dependence on clinical trial outcomes
- Limited financial resources compared to larger competitors
- No products currently on the market
- Potential for regulatory delays
Opportunities
- Positive clinical trial results for VK2809 and VK2735
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing prevalence of NASH and obesity
Threats
- Competition from other companies developing NASH and obesity treatments
- Failure to obtain regulatory approval for drug candidates
- Adverse events in clinical trials
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- NVO
- MDGL
- AKRO
- ETNB
Competitive Landscape
Viking Therapeutics is a smaller player competing against larger, more established pharmaceutical companies. Its success depends on demonstrating superior efficacy and safety compared to existing and emerging therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the advancement of clinical programs, not by revenue. Stock price has fluctuated significantly based on clinical trial news.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and regulatory approvals for VK2809 and VK2735. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing VK2809 and VK2735 into later-stage clinical trials and exploring potential partnerships.
Summary
Viking Therapeutics is a clinical-stage company with promising drug candidates targeting large markets like NASH and obesity. The company's success hinges on positive clinical trial results, especially for VK2809 and VK2735. While it faces competition from larger pharmaceutical companies, positive data readouts could significantly increase its value. Risks include clinical trial failures and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company presentations
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viking Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-29 | President, CEO & Director Dr. Brian Lian Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 48 | |
Full time employees 48 | |||
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.